|
03 Feb 2020 |
AntiCancer Inc. to Target Its Oral Recombinant Methioninase Against 2019-nCoV Coronavirus
|
|
02 Feb 2020 |
CHMP Recommends Approval of Lilly's New Fast-Acting Mealtime Insulin to Improve Glycemic Control in Adults with Diabetes
|
|
02 Feb 2020 |
Rybelsus® (oral semaglutide) recommended for approval for the treatment of adults with type 2 diabetes by the European regulatory authorities
|
|
31 Jan 2020 |
Rani Therapeutics Announces Positive Phase I Study Results of Oral Octreotide using RaniPill™
|
|
30 Jan 2020 |
Theraly Fibrosis Awarded $3.9 Million SBIR Phase II Grant to Support Development of TLY012 for Chronic Pancreatitis
|
|
30 Jan 2020 |
Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency
|
|
28 Jan 2020 |
Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer’s Disease
|
|
27 Jan 2020 |
Positive Results from Phase III, Split-Face, Head-to-Head Study Comparing OnabotulinumtoxinA and PrabotulinumtoxinA in the Treatment of Crow’s Feet Lines Published in Dermatologic Surgery
|
|
27 Jan 2020 |
NeoImmuneTech Received U.S. FDA Clearance of IND Application for Phase 1b/2a Study of Hyleukin-7™ (NT-I7) and KEYTRUDA® (Pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors
|
|
27 Jan 2020 |
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
|
|
23 Jan 2020 |
Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer
|
|
22 Jan 2020 |
Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial
|
|
21 Jan 2020 |
Stealth BioTherapeutics Initiates First-in-Human Study of SBT-272
|
|
17 Jan 2020 |
Rybelsus label updated with additional information from the PIONEER 6 CV outcomes trial
|
|
13 Jan 2020 |
Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
|
|
13 Jan 2020 |
MIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA (pegloticase injection) Indicates Significant Improvement in Response Rate
|
|
12 Jan 2020 |
Codexis and Nestlé Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic Collaboration Agreement
|
|
09 Jan 2020 |
Cybrexa Therapeutics Announces CBX-12 as Lead Development Program
|
|
09 Jan 2020 |
Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration
|
|
09 Jan 2020 |
CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis
|
|
09 Jan 2020 |
Entrada Therapeutics Announces ENTR-501 for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
|
|
09 Jan 2020 |
Bicycle Therapeutics and Cancer Research UK to Collaborate on Development of New Bicycle® Immuno-oncology Candidate, BT7401
|
|
08 Jan 2020 |
Bone Biologics Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation
|
|
07 Jan 2020 |
Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise
|
|
06 Jan 2020 |
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis
|
